KIN
Kindred Biosciences, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 7, 9:05 AM
    • Kindred Biosciences (NASDAQ:KIN): Q3 EPS of -$0.29 beats by $0.04.
    • Cash and cash equivalents of $62.5M
    • Press Release
    | Mon, Nov. 7, 9:05 AM
  • Fri, Nov. 4, 7:42 AM
    • Theravance Biopharma (NASDAQ:TBPH) initiated with Overweight rating and $42 (71% upside) price target by Piper Jaffray.
    • Viveve Medial (Pending:VIVE) initiated with Buy rating and $8 (59% upside) price target by B. Riley.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Buy rating and $164 (29% upside) price target by Deutsche Bank.
    • Halozyme Therapeutics (NASDAQ:HALO) initiated with Buy rating and $12 (42% upside) price target by Deutsche Bank.
    • Cynosure (NASDAQ:CYNO) initiated with Buy rating and $60 (47% upside) price target by Aegis Capital.
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) initiated with Hold rating and $9.50 (10% upside) price target by Deutsche Bank.
    • Aurinia Pharmaceuticals (NASDAQ:AUPH) initiated with Speculative Buy rating and $8 (214% upside) price target by Mackie Research Capital.
    • Achaogen (NASDAQ:AKAO) initiated with Buy rating and $10 (166% upside) price target by Aegis Capital.
    • Kindred Biosciences (NASDAQ:KIN) initiated with Buy rating and $7.50 (46% upside) price target by Ladenburg Thalmann.
    • Global Blood Therapeutics (NASDAQ:GBT) initiated with Buy rating and $47 (210% upside) price target by Roth Capital.
    • Obalon Therapeutics (Pending:OBLN) initiated with Buy rating and $28 (207% upside) price target by Canaccord Genuity. Initiated with Buy rating and $18 (97% upside) price target by Stifel Nicolaus.
    | Fri, Nov. 4, 7:42 AM
  • Mon, Aug. 8, 4:13 PM
    | Mon, Aug. 8, 4:13 PM
  • Thu, May 5, 8:42 AM
    • Kindred Biosciences (NASDAQ:KIN): Q1 EPS of -$0.31 beats by $0.01.
    | Thu, May 5, 8:42 AM
  • Wed, Mar. 2, 4:03 PM
    • Kindred Biosciences (NASDAQ:KIN): Q4 EPS of -$0.32 beats by $0.12.
    | Wed, Mar. 2, 4:03 PM
  • Nov. 9, 2015, 9:15 AM
    • Kindred Biosciences (NASDAQ:KIN): Q3 EPS of -$0.36 beats by $0.08.
    | Nov. 9, 2015, 9:15 AM
  • Aug. 10, 2015, 9:09 AM
    • Kindred Biosciences (NASDAQ:KIN): Q2 EPS of -$0.35 beats by $0.09.
    | Aug. 10, 2015, 9:09 AM
  • May 8, 2015, 9:05 AM
    • Kindred Biosciences (NASDAQ:KIN): Q1 EPS of -$0.34 beats by $0.07.
    | May 8, 2015, 9:05 AM
  • Mar. 12, 2015, 4:14 PM
    • Kindred Biosciences (NASDAQ:KIN): Q4 EPS of -$0.34 beats by $0.09.
    | Mar. 12, 2015, 4:14 PM
  • Dec. 4, 2014, 7:24 AM
    • Thinly-traded nano cap Kindred Biosciences (NASDAQ:KIN) plummets 24% premarket on robust volume in response to its announcement that it is terminating its atopic dermatitis program, including its AtoKin study, in favor of more promising programs.
    • CEO Richard Chin says the main reason for the move is the rapid uptake of a recently-launched atopic dermatitis product that has raised the bar for future competitors. He doesn't believe AtoKin is differentiated enough to be a market leader.
    • Kindred has been in a down trend March. Shares have dropped almost 75% since the March 14 peak of $26.99.
    • BMO analyst Alex Arfaei says Kindred's decision is "incrementally positive" for Zoetis' (NYSE:ZTS) Apoquel, which could hit $300M in sales by 2019.
    | Dec. 4, 2014, 7:24 AM | 3 Comments
  • Nov. 13, 2014, 4:21 PM
    • Kindred Biosciences (NASDAQ:KIN): Q3 EPS of -$0.31 beats by $0.14.
    • Cash and equivalents of $106.4M.
    | Nov. 13, 2014, 4:21 PM
  • Sep. 3, 2014, 4:29 PM
    • Kindred Biosciences (KIN +0.7%) CFO Stephen S. Galliker retires effective August 29, 2014. He will serve as a consultant for up to two more years at a rate of $5,000 per month for up to 20 hours of service per month and $250 per hour for services beyond 20 hours. In year two of the contract, the company will pay him $250 per hour of service. Services per month are not to exceed 80 hours and the maximum outlay to Mr. Galliker is capped at $200K/year.
    | Sep. 3, 2014, 4:29 PM | 1 Comment
  • Aug. 21, 2014, 1:11 PM
    | Aug. 21, 2014, 1:11 PM | 1 Comment
  • Aug. 21, 2014, 9:10 AM
    | Aug. 21, 2014, 9:10 AM
  • Aug. 20, 2014, 5:07 PM
    • Shares of Kindred Biosciences (NASDAQ:KIN) plummet 34% on robust volume in response to the company's disclosure that its lead product candidate, CereKin (diacerein), an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, failed to achieve its primary endpoint in a clinical trial.
    • The failure was due to a higher-than-expected placebo response rate and statistical variability. In the high dose (20 mg/kg) cohort, the response rate was comparable to human studies but the dropout rate was too high to achieve statistical significance.
    | Aug. 20, 2014, 5:07 PM | 2 Comments
  • Aug. 13, 2014, 5:26 PM
    • Kindred Biosciences (KIN -1.4%) Q2 results: Revenues: $0; Net Loss: ($8.1M) (-999%); Loss Per Share: ($0.42) (-223.1%); Quick Assets: $112.4M (+72.1%).
    • No financial guidance given.
    | Aug. 13, 2014, 5:26 PM